Tetraneuron

Tetraneuron, founded in 2012 as a spin-off from Spain’s Cajal Institute (CSIC), develops innovative gene therapies for neurodegenerative diseases. Its lead therapy, TET-101, targets E2F4 phosphorylation to restore key biological processes in Alzheimer’s. Backed by 30+ years of neuroscience expertise and a team from academia and pharma, Tetraneuron has completed key preclinical milestones, engaged with EMA and FDA, secured global patents, and aims to start first-in-human trials in 2026.